Biotech7 months ago
Almirall and Eloxx Sign an Exclusive Licensing Agreement for Rare Dermatological Pathologies
Almirall has acquired exclusive rights to Eloxx Pharmaceuticals' ZKN-013, a potentially promising treatment for rare dermatological diseases. Almirall gains global development and commercialization rights, paying Eloxx...